
Claims

1. A compound represented by Formula 1 below, or its pharmaceutically acceptable salt, hydrate, **or** solvate~~, prodrug, or composite~~:




Formula 1

wherein in Formula 1,


R_1, R_2 and R_3 each independently represents hydrogen, ~~lower~~**C_1-C_6** alkyl optionally substituted with halogen, ~~lower~~**C_1-C_6** alkoxy optionally substituted with halogen, or halogen,

R_4 represents methyl or amine, and

R_8 is substituted with a radical of Formula 2 below, or substituted with a radical of Formula 3 below,



Formula 2



Formula 3

wherein, R_5, R_6 and R_7 each independently represents hydrogen, ~~lower~~**C_1-C_6** alkyl optionally substituted with halogen, hydroxy, ~~lower~~**C_1-C_6** alkoxy **optionally substituted with halogen**, or halogen, and

~~R_9 represents lower alkyl~~

wherein when the radical of Formula 2 is substituted for R_8,

two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents C_1-C_6 alkyl optionally substituted with halogen, C_1-C_6 alkoxy optionally substituted with halogen, or halogen, and from among R_5, R_6 and R_7, one or two each independently represents hydrogen, C_1-C_6 alkyl optionally substituted with halogen, hydroxy, C_1-C_6 alkoxy, or halogen;

two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents trifluoromethyl, fluoro, or

trifluoromethoxy, and from among R_5, R_6 and R_7, one or two each independently represents hydrogen, methoxy, chlorine, fluoro, or hydroxy; or

R_1 represents halogen, R_2, R_3, R_5, and R_7 represents hydrogen, and R_6 represents C_1-C_6 alkoxy,and

wherein when the radical of Formula 3 is substituted for R_8,

two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents C_1-C_6 alkyl optionally substituted with halogen, C_1-C_6 alkoxy optionally substituted with halogen, or halogen, R_4 represents amine, and R_9 represents C_1-C_6 alkyl, or

R_4 represents amine, two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents trifluoromethyl, fluoro, or trifluoromethoxy, and R_9 represents methyl or ethyl.

~~2. The compound or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, or composite, as claimed in claim 1, wherein when the radical of Formula 2 is substituted for R_8,~~

~~two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents lower alkyl optionally substituted with halogen, lower alkoxy optionally substituted with halogen, or halogen, preferably fluoro or chlorine, R_4 represents methyl, or amine, and from among R_5, R_6 and R_7, one or two each independently represents hydrogen, lower alkyl optionally substituted with halogen, hydroxy, lower alkoxy, or halogen;~~

~~two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents trifluoromethyl, fluoro, or trifluoromethoxy, R_4 represents methyl or amine, and from among R_5, R_6 and R_7, one or two each independently represents hydrogen, methoxy, chlorine, fluoro, trifluoromethyl or hydroxy; or~~

~~R_1 represents halogen, preferably chlorine, R_4 represents methyl or amine, R_2, R_3, R_5, and R_7 each represents hydrogen, and R_6 represents alkoxy, preferably methoxy.~~

~~3~~2. The compound or its pharmaceutically acceptable salt, hydrate, **or** solvate~~, prodrug, or composite~~, as claimed in claim 1, wherein when the radical of Formula 2 is substituted for R_8,

R_1 represents trifluoromethyl, or trifluoromethoxy, R_2 and R_3 represent hydrogen, R_4 represents methyl~~ or amine~~, and from among R_5, R_6 and R_7, one or two each independently represents hydrogen, hydroxy, methoxy, or chlorine;

R_1 represents chlorine, R_4 represents methyl **or amine**, R_2, R_3, R_5 and R_7 each represents hydrogen, and R_6 represents methoxy; or

R_2 represents fluoro, trifluoromethyl, or trifluoromethoxy, R_1 and R_3 each represents hydrogen, R_4 represents methyl or amine, and from among R_5, R_6 and R_7, one or two each independently represents hydrogen, hydroxy, methoxy, trifluoromethyl or chlorine.

~~4. The compound or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, or composite, as claimed in claim 1, wherein when the radical of Formula 3 is substituted for R_8,~~

~~two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents lower alkyl optionally substituted with halogen, lower alkoxy optionally substituted with halogen, or halogen, R_4 represents amine, and R9 represents lower alkyl, or~~

~~R_4 represents amine, two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents trifluoromethyl, fluoro, or trifluoromethoxy, and R_9 represents~~

~~methyl or ethyl.~~

~~5~~3. The compound or its pharmaceutically acceptable salt, hydrate, **or** solvate~~, prodrug, or composite~~, as claimed in claim 1, wherein when the radical of Formula 3 is substituted for R_8, R_1 represents trifluoromethoxy, R_2 and R_3 each represents hydrogen, R_4 represents amine, and R_9 represents ethyl.

~~6~~4. The compound, or its pharmaceutically acceptable salt, hydrate, **or** solvate~~, prodrug, or composite~~, as claimed in claim 1, wherein the compound **is~~comprises~~** (4-(2-fluorophenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(3-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(2-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(2-trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (5-methyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (4-(4-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(2-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(4-fluorophenyl)piperazine-1-yl)(5-methyl-3-(2-trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (3-(2-chlorophenyl)-5-methylisoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(3-(3-fluorophenyl)-5-methylisoxazol-4-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(3-

methoxyphenyl)piperazine-1-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(3-(2-fluorophenyl)-5-methylisoxazol-4-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (4-(2-fluorophenyl)piperazine-1-yl)(5-methyl-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(5-methyl-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(3-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(2-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (5-methyl-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (4-(4-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(2-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(4-

(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(4-fluorophenyl)piperazine-1-yl)(5-methyl-3-(4-trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(2-fluorophenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(3-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(2-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(2-trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (5-methyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (4-(4-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(2-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(4-fluorophenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(2-fluorophenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(3-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(2-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (5-methyl-3-(3-trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (4-(4-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(2-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(4-fluorophenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(2-

fluorophenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(3-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(2-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-trifluoromethyl)phenyl)piperazine-1-yl)methanone, (4-(4-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(2-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(4-fluorophenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(3-

(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-

(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, 5-amino-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-(trifluoromethylphenyl)piperazine-1-yl)methanone, (5-amino-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3-

methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3-(trifluoromethyl)phenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-fluorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-trifluoromethyl)phenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(4-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(4-fluorophenyl)piperazine-1-yl)methanone, ethyl-1-(5-amino-3-(2-chlorophenyl)isoxazol-4-carbonyl)piperidine-4-carboxylate, methyl-1-(5-amino-3-(2-fluorophenyl)isoxazol-4-carbonyl)piperidine-4-carboxylate, ethyl-1-(5-amino-3-(2-trifluoromethoxy)phenyl)isoxazol-4-carbonyl)piperidine-4-carboxylate, or ethyl-1-(5-amino-3-(2-(trifluoromethyl)phenyl)isoxazol-4-carbonyl)piperidine-4-carboxylate.

~~7~~5. The compound or its pharmaceutically acceptable salt, hydrate, **or** solvate~~, prodrug, or composite~~, as claimed in any one of claims 1**,** ~~3~~2 **and** ~~to~~ ~~5~~3, wherein the compound **is**~~comprises~~ (4-(3-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(2-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(2-trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (3-(2-chlorophenyl)-5-methylisoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(3-(3-fluorophenyl)-5-methylisoxazol-4-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (3-(3-fluorophenyl)-5-methylisoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(3-(2-fluorophenyl)-5-methylisoxazol-4-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(5-methyl-3-(4-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(5-methyl-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (3-(2-fluorophenyl)-5-methylisoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (4-(3-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(2-hydroxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)methanone, (4-(3,4-dichlorophenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (4-(3-methoxyphenyl)piperazine-1-yl)(5-methyl-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-chlorophenyl)isoxazol-4-yl)(4-(2-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-

1-yl)methanone, (5-amino-3-(3-fluorophenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-fluorophenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(2-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(2-trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethyl)phenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3,4-dichlorophenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(3-methoxyphenyl)piperazine-1-yl)methanone, (5-amino-3-(3-(trifluoromethoxy)phenyl)isoxazol-4-yl)(4-(2-hydroxyphenyl)piperazine-1-yl)methanone, ethyl-1-(5-amino-3-(2-chlorophenyl)isoxazol-4-carbonyl)piperidine-4-carboxylate, or ethyl-1-(5-amino-3-(2-trifluoromethoxy)phenyl)isoxazol-4-carbonyl)piperidine-4-carboxylate.

~~8~~6. A method for preparing the compound represented by Formula 1, as claimed in claim 1, the method comprising the steps of:


reacting a compound represented by Formula 4 below with hydroxylammoniumchloride in the presence of a base to produce a compound represented by Formula 5 below;

chlorinating the compound represented by Formula 5 so as to produce a compound represented by Formula 6 below;


cyclizing the compound represented by Formula 6 so as to produce a compound represented by Formula 7 below as an isoxazol compound;

removing R_{10} as an alkyl group of Formula 7 so as to produce a compound represented by Formula 8; and


reacting the compound represented by Formula 8 with a compound represented by Formula 2 or Formula 3 so as to produce a compound represented by Formula 9a or Formula 9b:




Formula 2




Formula 3




Formula 4




Formula 5




Formula 6




Formula 7



Formula 8



Formula 9a



Formula 9b

wherein in Formulas above,

R_1 to R_9 are the same as defined in claim 1, and

R_{10} represents a ~~lower~~**C_1-C_6** alkyl group~~, preferably methyl, ethyl or an isopropyl group~~.

~~9. The method as claimed in claim 8, wherein the method is carried out in the presence of a general solvent and/or an acid or a base, in which the solvent, the acid and the base have no adverse effect on a reaction.~~

~~10~~7. The method as claimed in claim ~~9~~6 wherein **the method for preparing the compound represented by Formula 1 is performed using** ~~the~~**a** solvent **which** is at least one kind selected from the group consisting of tetrahydrofuran, methylene chloride, ethanol, N,N-dimethylformamide, N,N-dimethylacetamide, ethylacetate, tert-butanol, toluene and dioxane.


~~11~~8. The method as claimed in claim ~~9~~6, wherein **the method for preparing the compound represented by Formula 1 is performed using** the base **which** is at least one kind selected from the group consisting of pyridine, triethylamine, diethylamine, sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, sodium

methoxide, sodium ethoxide, sodium t-butoxide, potassium t-butoxide, lithium aluminum hydride, lithium borohydride, sodium nitrate and cesium carbonate.

~~12~~9. The method as claimed in claim ~~9~~6, wherein **the method for preparing the compound represented by Formula 1 is performed using** ~~**the**~~**a** acid is at least one kind selected from the group consisting of trifluoroacetic acid, hydrochloric acid, nitric acid, sulfuric acid, bromic acid, zinc bromide and acetic acid.

~~13. A composition comprising the compound as claimed in any one of claims 1 to 6, or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, or composite, and its pharmaceutically acceptable carrier or excipient.~~

~~14~~10. A pharmaceutical composition for treating or preventing **an influenza** virus infection, the pharmaceutical composition comprising ~~**the compound as claimed in any one of claims 1 to 6**~~**a compound represented by Formula 1 below**, or its pharmaceutically acceptable salt, hydrate, **or** solvate~~**, prodrug, or composite**~~, and its pharmaceutically acceptable carrier or excipient**:**




Formula 1

wherein in Formula 1,


R_1, R_2 and R_3 each independently represents hydrogen, C_1-C_6 alkyl optionally substituted with halogen, C_1-C_6 alkoxy optionally substituted with halogen, or halogen,

R_4 represents methyl or amine, and

R_8 is substituted with a radical of Formula 2 below, or substituted with a radical of Formula 3 below,



Formula 2



Formula 3

wherein, R_5, R_6 and R_7 each independently represents hydrogen, C_1-C_6 alkyl optionally substituted with halogen, hydroxy, C_1-C_6 alkoxy optionally substituted with halogen, or halogen, and

wherein when the radical of Formula 2 is substituted for R_8,

two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents C_1-C_6 alkyl optionally substituted with halogen, C_1-C_6 alkoxy optionally substituted with halogen, or halogen, and from among R_5, R_6 and R_7, one or two each independently represents hydrogen, C_1-C_6 alkyl optionally substituted with halogen, hydroxy, C_1-C_6 alkoxy, or halogen;

two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents trifluoromethyl, fluoro, or trifluoromethoxy, and from among R_5, R_6 and R_7, one or two each independently represents hydrogen, methoxy, chlorine, fluoro, or hydroxy; or

R_1 represents halogen, R_2, R_3, R_5, and R_7 represents hydrogen, and R_6 represents C_1-C_6 alkoxy,

wherein when the radical of Formula 3 is substituted for R_8,

two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents C_1-C_6 alkyl optionally substituted with halogen, C_1-C_6 alkoxy optionally substituted with halogen, or halogen, R_4 represents amine, and R_9 represents C_1-C_6 alkyl, or

R_4 represents amine, two from among R_1, R_2 and R_3 represent hydrogen, the remaining one represents trifluoromethyl, fluoro, or trifluoromethoxy, and R_9 represents methyl or ethyl.

~~15~~11. **The pharmaceutical composition for treating or preventing the influenza virus infection as claimed in claim ~~14~~10~~A combination comprising the compound as claimed in any one of claims 1 to 6, or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, or composite, together with another virus infection therapeutic or preventive agent such as~~ wherein the pharmaceutical composition further comprises at least one selected from the group consisting of** Zanamivir, Oseltamivir, Amantadine **~~or~~and** Rimantadine **as an active ingredient**.

~~16. Use of the compound as claimed in any one of claims 1 to 6, or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, or composite, for preparing a pharmaceutical composition for treatment or prevention of virus infection.~~

~~17. A method for preventing or treating virus infection, comprising administering a therapeutically effective amount of the compound as claimed in any one of claims 1 to 6, or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, or composite, to mammals, including humans, requiring virus infection treatment or prevention.~~